Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents.
暂无分享,去创建一个
[1] J. Bernstein,et al. Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency. , 2015, Immunotherapy.
[2] J. Bernstein,et al. Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks. , 2015, The journal of allergy and clinical immunology. In practice.
[3] J. Bernstein,et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[4] K. Beusterien,et al. The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe. , 2014, Allergy and asthma proceedings.
[5] C. Hack,et al. Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema. , 2013, British journal of clinical pharmacology.
[6] J. Sheikh,et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. , 2013, The Journal of allergy and clinical immunology.
[7] T. Machnig,et al. Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: a systematic literature review. , 2013, Allergy and asthma proceedings.
[8] R. Lockey,et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[9] R. Ree,et al. Immunosafety of Recombinant Human C1-Inhibitor in Hereditary Angioedema: Evaluation of IgE Antibodies , 2013, Clinical Drug Investigation.
[10] J. Speight,et al. Content Validity of Visual Analog Scales to Assess Symptom Severity of Acute Angioedema Attacks in Adults with Hereditary Angioedema , 2012, The Patient - Patient-Centered Outcomes Research.
[11] M. Triggiani,et al. Efficacy and safety of recombinant human C1‐inhibitor for the treatment of attacks of hereditary angioedema: European open‐label extension study , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[12] D. Meyer‐Olson,et al. Hereditary angioedema (HAE) in children and adolescents—a consensus on therapeutic strategies , 2012, European Journal of Pediatrics.
[13] C. Town,et al. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. , 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[14] J. Nuijens,et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. , 2010, The Journal of allergy and clinical immunology.
[15] A. Sheffer,et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. , 2010, The New England journal of medicine.
[16] William H. Yang,et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. , 2010, The New England journal of medicine.
[17] H. Joller-jemelka,et al. Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations. , 2008, Journal of immunological methods.
[18] J. Hagan,et al. Acute pancreatitis due to hereditary angioedema. , 2006, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[19] K. Bork,et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. , 2006, The American journal of medicine.